Drug profile · INN
liraglutide
SAXENDA
liraglutide (SAXENDA) is a glucagon-like peptide 1 receptor agonist. Associated with Teva Pharma GmbH. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — liraglutide
- US status
- approved
- Class
- Alimentary tract and metabolism (A10)
- Route
- SUBCUTANEOUS
- Patents
- 3
- Programs
- 8
- Data quality
- 0.89
Quick answer
liraglutide (SAXENDA) is a glucagon-like peptide 1 receptor agonist. Associated with Teva Pharma GmbH. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucagon-like peptide 1 receptor agonist
Primary target: Glucagon-like peptide 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
-
US 10851146
Method for preparing liraglutide intermediate polypeptide
granted -
US 9486414
Method for delivering liraglutide preparations into a lumen of the intestinal tract using a swallowable drug delivery device
granted -
US 8809271
Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
granted
Frequently asked questions
What is liraglutide?
liraglutide (SAXENDA) is a glucagon-like peptide 1 receptor agonist. Associated with Teva Pharma GmbH. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for liraglutide?
SAXENDA is a marketed brand name for liraglutide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of liraglutide?
liraglutide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.